+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Specialty Pharmaceuticals Market - Global Forecast to 2030- Product Image
Specialty Pharmaceuticals Market - Global Forecast to 2030- Product Image
Sale

Specialty Pharmaceuticals Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6012056
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Specialty Pharmaceuticals Market grew from USD 129.23 billion in 2024 to USD 182.24 billion in 2025. It is expected to continue growing at a CAGR of 39.91%, reaching USD 969.50 billion by 2030.

The specialty pharmaceuticals sector has undergone a significant transformation over the past decade, driven by the emergence of precision therapies, complex biologics and advanced delivery systems. As healthcare systems grapple with rising chronic disease burden and the need for targeted interventions, this segment has become a cornerstone of modern therapeutics. Innovations in biotechnology and synthetic chemistry have accelerated the development of novel agents, while regulators and payers adapt to the nuances of high-cost, high-value treatments. Amid these changes, stakeholders-ranging from drug developers to clinicians-must navigate intricate regulatory pathways, complex manufacturing processes and evolving reimbursement frameworks. This introduction lays the groundwork for understanding the forces reshaping specialty pharma, setting the stage for an exploration of transformative market shifts, the impact of impending tariff policies, and the critical segmentation, regional and competitive insights that will guide strategic decision-making in 2025 and beyond.

Transformative Shifts Reshaping the Specialty Pharma Arena

The specialty pharma landscape is undergoing transformative shifts fueled by scientific breakthroughs, policy reforms and shifting patient demographics. Advances in immunotherapy agents, targeted therapies and gene editing technologies are redefining treatment paradigms, moving the industry from broad-spectrum small molecules to highly specialized biologic and cell‐based platforms. Concurrently, rising demand for personalized medicine compels manufacturers to invest in robust supply chains and scalable manufacturing technologies. Digital health integration, including remote patient monitoring and telepharmacy solutions, is enhancing drug adherence and outcomes, while real-world evidence generation influences payer coverage decisions. Strategic collaborations between research institutions and biopharma companies intensify innovation pipelines, narrowing time-to-market. Meanwhile, value-based contracting emerges as a dominant model, aligning stakeholder incentives around patient outcomes rather than unit sales. These intersecting dynamics are reshaping how products are developed, priced and delivered, challenging incumbents to adopt agile strategies and invest in next-generation platforms to maintain competitive advantage.

Cumulative Impact of United States Tariffs in 2025

The introduction of new U.S. tariffs in 2025 has created a noticeable ripple effect across the specialty pharmaceuticals supply chain. Manufacturers relying on imported active pharmaceutical ingredients and biologic components must now contend with increased input costs, prompting some to explore domestic sourcing or to renegotiate supplier contracts. These cost pressures have intensified scrutiny of pricing structures and prompted a reevaluation of product portfolios, particularly those with thin margins. In response, several global companies have initiated reshoring efforts, investing in local biotechnology and synthetic chemistry capabilities to mitigate tariff exposure. Moreover, payers and providers are closely monitoring cost escalations, with some adopting stricter formulary management protocols and prior authorization requirements. To sustain innovation investments, firms are leveraging strategic partnerships and co-development agreements to share financial risk and accelerate commercialization. Collectively, these adaptations underscore the sector’s resilience and its capacity to absorb regulatory headwinds while preserving patient access to life-saving therapies.

Key Segmentation Insights Driving Market Differentiation

A nuanced understanding of market segmentation reveals opportunities to tailor strategies and maximize return on investment. When examined by drug type, the distinction between biologics and small molecule drugs highlights divergent development pathways and manufacturing complexities, with biologics commanding premium pricing and extended regulatory oversight. In the therapeutic area dimension, cardiovascular, endocrine, infectious, neurological and oncology treatments each present unique growth vectors; within endocrine, diabetes subdivides into type 1 and type 2 management and thyroid therapies, while infectious disease pivots on antibacterials versus antivirals, and oncology splits across chemotherapy, immunotherapy agents and targeted therapies. Considering dosage form, inhalation and topical preparations cater to localized delivery needs, whereas oral capsules and tablets, along with injectable formats such as vials and pre-filled syringes, serve systemic indications. Distribution channels span hospital, retail and online pharmacies, each demanding tailored logistics and patient engagement models. Applications range from acute infections and pain management to chronic conditions like asthma and rheumatoid arthritis, extending even to cosmetic uses. Patient population segmentation differentiates adults, geriatrics and pediatrics, while manufacturing technology hinges on biotechnology versus synthetic chemistry platforms. Finally, end-user categories-clinics, home healthcare and hospitals-and pricing tiers of generic, premium and value drugs further inform targeted go-to-market approaches.

Regional Insights: Mapping Growth Across Global Markets

Regional dynamics continue to shape strategic priorities as each market presents distinct regulatory landscapes and access pathways. In the Americas, strong payer infrastructure and established reimbursement frameworks underpin rapid adoption of novel therapies, though cost containment measures and formulary restrictions remain rigorous. Europe, Middle East & Africa markets are characterized by diverse regulatory requirements, varying health economics assessments and evolving tender processes; here, manufacturers must navigate a mosaic of country-specific pricing and health technology assessment protocols. Asia-Pacific is distinguished by high-growth potential in emerging economies, where rising healthcare investment, expanding private hospital networks and increasing insurance penetration drive demand for specialty drugs; yet market access hurdles and local manufacturing mandates call for collaborative licensing and joint-venture strategies. By aligning portfolio priorities with regional policy environments and patient access models, companies can optimize launch sequencing and resource allocation to capture value across global markets.

Key Company Insights: Competitive Dynamics and Strategic Moves

Competitive dynamics in specialty pharmaceuticals center on innovation engines, strategic alliances and portfolio diversification. AbbVie Inc. and Amgen Inc. continue to leverage robust biologics pipelines to drive growth, while Bristol Myers Squibb Company emphasizes immuno-oncology collaborations. Endo International PLC has intensified its focus on pain management and endocrinology, whereas F. Hoffmann-La Roche Ltd. maintains leadership in oncology through targeted therapy expansions. Gilead Sciences, Inc. is advancing antiviral and inflammatory disease programs, and Hyphens Pharma International Limited is carving a niche in high-potency and controlled-release formulations. Merck KGaA and Novartis AG prioritize cell and gene therapy innovation, whereas Pfizer Inc. balances immunotherapy development with vaccine portfolio enhancements. Sanofi S.A. accelerates diabetes and rare disease therapeutics, and Teva Pharmaceutical Industries Ltd. pursues biosimilar introductions to challenge established brands. UnitedHealth Group’s integrated care services influence distribution models, while Viatris Inc. capitalizes on value drug production and generic penetration. By benchmarking against these leading players, organizations can identify white-space opportunities and formulate partnership or M&A strategies that bolster their competitive positioning.

Actionable Recommendations for Industry Leaders

Industry leaders should adopt a multi-pronged approach to sustain growth and innovation. First, invest in flexible manufacturing technologies that accommodate both biotechnology and synthetic chemistry processes, enabling rapid scale-up and reshoring where tariffs pose a risk. Second, pursue strategic alliances and co-development partnerships to share R&D costs and expedite time-to-market, focusing on synergistic portfolios in immuno-oncology, metabolic disorders and gene therapies. Third, implement value-based contracting frameworks that align pricing with real-world outcomes, bolstering payer engagement and expanding access in cost-constrained environments. Fourth, leverage digital health platforms for remote monitoring, patient adherence analytics and personalized care pathways, thereby enhancing clinical outcomes and generating robust real-world evidence. Fifth, optimize regional launch strategies by tailoring regulatory dossiers, pricing models and distribution partnerships to local market dynamics. Finally, deepen market intelligence capabilities across segmentation, regional insights and competitive landscapes to anticipate shifts and recalibrate strategies proactively. Together, these actions will equip leaders to navigate uncertainty, capitalize on emerging trends and deliver sustainable value.

Conclusion: Synthesizing Trends and Strategic Imperatives

As specialty pharmaceuticals continue their trajectory toward greater complexity and value-based care, stakeholders must remain vigilant and adaptable. Emerging technologies, evolvingpayer models and geopolitically influenced trade policies will define the contours of future success. A clear segmentation framework enables precise targeting of patient populations and end-users, while regional insights inform resource deployment and market entry tactics. Competitive intelligence on leading companies highlights strategic gaps and partnership openings. By integrating these insights into cohesive strategic roadmaps, organizations can accelerate innovation, optimize commercial performance and deliver differentiated therapies to patients in need. Ultimately, the capacity to anticipate and respond to market shifts will determine which players lead the next wave of specialty pharmaceutical breakthroughs.

Market Segmentation & Coverage

This research report categorizes the Specialty Pharmaceuticals Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Biologics
  • Small Molecule Drugs
  • Cardiovascular Disorders
  • Endocrine Disorders
    • Diabetes
      • Type 1
      • Type 2
    • Thyroid Disorders
  • Infectious Diseases
    • Antibacterials
    • Antivirals
  • Neurological Disorders
  • Oncology
    • Chemotherapy
    • Immunotherapy Agents
    • Targeted Therapy
  • Inhalation
  • Injectable Administration
    • Pre-Filled Syringes
    • Vials
  • Oral Administration
    • Capsules
    • Tablets
  • Topical Administration
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Acute Conditions
    • Infections
    • Pain Management
  • Chronic Diseases
    • Asthma
    • Rheumatoid Arthritis
  • Cosmetic Applications
  • Adults
  • Geriatrics
  • Pediatrics
  • Biotechnology
  • Synthetic Chemistry
  • Clinics
  • Home Healthcare
  • Hospitals
  • Generic Drugs
  • Premium Drugs
  • Value Drugs

This research report categorizes the Specialty Pharmaceuticals Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Specialty Pharmaceuticals Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie Inc.
  • Amgen Inc.
  • Bristol Myers Squibb Company
  • Endo International PLC
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Hyphens Pharma International Limited
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • UnitedHealth Group
  • Viatris Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Specialty Pharmaceuticals Market, by Drug Type
8.1. Introduction
8.2. Biologics
8.3. Small Molecule Drugs
9. Specialty Pharmaceuticals Market, by Therapeutic Area
9.1. Introduction
9.2. Cardiovascular Disorders
9.3. Endocrine Disorders
9.3.1. Diabetes
9.3.1.1. Type 1
9.3.1.2. Type 2
9.3.2. Thyroid Disorders
9.4. Infectious Diseases
9.4.1. Antibacterials
9.4.2. Antivirals
9.5. Neurological Disorders
9.6. Oncology
9.6.1. Chemotherapy
9.6.2. Immunotherapy Agents
9.6.3. Targeted Therapy
10. Specialty Pharmaceuticals Market, by Dosage Form
10.1. Introduction
10.2. Inhalation
10.3. Injectable Administration
10.3.1. Pre-Filled Syringes
10.3.2. Vials
10.4. Oral Administration
10.4.1. Capsules
10.4.2. Tablets
10.5. Topical Administration
11. Specialty Pharmaceuticals Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Specialty Pharmaceuticals Market, by Application
12.1. Introduction
12.2. Acute Conditions
12.2.1. Infections
12.2.2. Pain Management
12.3. Chronic Diseases
12.3.1. Asthma
12.3.2. Rheumatoid Arthritis
12.4. Cosmetic Applications
13. Specialty Pharmaceuticals Market, by Patient Population
13.1. Introduction
13.2. Adults
13.3. Geriatrics
13.4. Pediatrics
14. Specialty Pharmaceuticals Market, by Manufacturing Technology
14.1. Introduction
14.2. Biotechnology
14.3. Synthetic Chemistry
15. Specialty Pharmaceuticals Market, by End-User
15.1. Introduction
15.2. Clinics
15.3. Home Healthcare
15.4. Hospitals
16. Specialty Pharmaceuticals Market, by Pricing Segment
16.1. Introduction
16.2. Generic Drugs
16.3. Premium Drugs
16.4. Value Drugs
17. Americas Specialty Pharmaceuticals Market
17.1. Introduction
17.2. Argentina
17.3. Brazil
17.4. Canada
17.5. Mexico
17.6. United States
18. Asia-Pacific Specialty Pharmaceuticals Market
18.1. Introduction
18.2. Australia
18.3. China
18.4. India
18.5. Indonesia
18.6. Japan
18.7. Malaysia
18.8. Philippines
18.9. Singapore
18.10. South Korea
18.11. Taiwan
18.12. Thailand
18.13. Vietnam
19. Europe, Middle East & Africa Specialty Pharmaceuticals Market
19.1. Introduction
19.2. Denmark
19.3. Egypt
19.4. Finland
19.5. France
19.6. Germany
19.7. Israel
19.8. Italy
19.9. Netherlands
19.10. Nigeria
19.11. Norway
19.12. Poland
19.13. Qatar
19.14. Russia
19.15. Saudi Arabia
19.16. South Africa
19.17. Spain
19.18. Sweden
19.19. Switzerland
19.20. Turkey
19.21. United Arab Emirates
19.22. United Kingdom
20. Competitive Landscape
20.1. Market Share Analysis, 2024
20.2. FPNV Positioning Matrix, 2024
20.3. Competitive Analysis
20.3.1. AbbVie Inc.
20.3.2. Amgen Inc.
20.3.3. Bristol Myers Squibb Company
20.3.4. Endo International PLC
20.3.5. F. Hoffmann-La Roche Ltd.
20.3.6. Gilead Sciences, Inc.
20.3.7. Hyphens Pharma International Limited
20.3.8. Merck KGaA
20.3.9. Novartis AG
20.3.10. Pfizer Inc.
20.3.11. Sanofi S.A.
20.3.12. Teva Pharmaceutical Industries Ltd.
20.3.13. UnitedHealth Group
20.3.14. Viatris Inc.
21. ResearchAI
22. ResearchStatistics
23. ResearchContacts
24. ResearchArticles
25. Appendix
List of Figures
FIGURE 1. SPECIALTY PHARMACEUTICALS MARKET MULTI-CURRENCY
FIGURE 2. SPECIALTY PHARMACEUTICALS MARKET MULTI-LANGUAGE
FIGURE 3. SPECIALTY PHARMACEUTICALS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PATIENT POPULATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PATIENT POPULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 20. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 22. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PRICING SEGMENT, 2024 VS 2030 (%)
FIGURE 24. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PRICING SEGMENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. AMERICAS SPECIALTY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. AMERICAS SPECIALTY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. UNITED STATES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 28. UNITED STATES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ASIA-PACIFIC SPECIALTY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. ASIA-PACIFIC SPECIALTY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. EUROPE, MIDDLE EAST & AFRICA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. EUROPE, MIDDLE EAST & AFRICA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. SPECIALTY PHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 34. SPECIALTY PHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SPECIALTY PHARMACEUTICALS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ENDOCRINE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY TYPE 1, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY TYPE 2, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ENDOCRINE DISORDERS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ANTIBACTERIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY VIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY TOPICAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ACUTE CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ACUTE CONDITIONS, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY CHRONIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY COSMETIC APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY BIOTECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY SYNTHETIC CHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PRICING SEGMENT, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PREMIUM DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY VALUE DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS SPECIALTY PHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ENDOCRINE DISORDERS, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS SPECIALTY PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ACUTE CONDITIONS, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS SPECIALTY PHARMACEUTICALS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS SPECIALTY PHARMACEUTICALS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS SPECIALTY PHARMACEUTICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PRICING SEGMENT, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS SPECIALTY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ENDOCRINE DISORDERS, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ACUTE CONDITIONS, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PRICING SEGMENT, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ENDOCRINE DISORDERS, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ACUTE CONDITIONS, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PRICING SEGMENT, 2018-2030 (USD MILLION)
TABLE 120. CANADA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 121. CANADA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 122. CANADA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ENDOCRINE DISORDERS, 2018-2030 (USD MILLION)
TABLE 123. CANADA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 124. CANADA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 125. CANADA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 126. CANADA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 127. CANADA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. CANADA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. CANADA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. CANADA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 131. CANADA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ACUTE CONDITIONS, 2018-2030 (USD MILLION)
TABLE 132. CANADA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 133. CANADA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 134. CANADA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 135. CANADA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. CANADA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PRICING SEGMENT, 2018-2030 (USD MILLION)
TABLE 137. MEXICO SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 138. MEXICO SPECIALTY PHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 139. MEXICO SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ENDOCRINE DISORDERS, 2018-2030 (USD MILLION)
TABLE 140. MEXICO SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 141. MEXICO SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 142. MEXICO SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 143. MEXICO SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 144. MEXICO SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. MEXICO SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. MEXICO SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. MEXICO SPECIALTY PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. MEXICO SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ACUTE CONDITIONS, 2018-2030 (USD MILLION)
TABLE 149. MEXICO SPECIALTY PHARMACEUTICALS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 150. MEXICO SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 151. MEXICO SPECIALTY PHARMACEUTICALS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 152. MEXICO SPECIALTY PHARMACEUTICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 153. MEXICO SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PRICING SEGMENT, 2018-2030 (USD MILLION)
TABLE 154. UNITED STATES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 156. UNITED STATES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ENDOCRINE DISORDERS, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 159. UNITED STATES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 160. UNITED STATES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 161. UNITED STATES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. UNITED STATES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. UNITED STATES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 165. UNITED STATES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ACUTE CONDITIONS, 2018-2030 (USD MILLION)
TABLE 166. UNITED STATES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 167. UNITED STATES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 170. UNITED STATES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PRICING SEGMENT, 2018-2030 (USD MILLION)
TABLE 171. UNITED STATES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC SPECIALTY PHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 174. ASIA-PACIFIC SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ENDOCRINE DISORDERS, 2018-2030 (USD MILLION)
TABLE 175. ASIA-PACIFIC SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 176. ASIA-PACIFIC SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 177. ASIA-PACIFIC SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 178. ASIA-PACIFIC SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 179. ASIA-PACIFIC SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. ASIA-PACIFIC SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. ASIA-PACIFIC SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. ASIA-PACIFIC SPECIALTY PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 183. ASIA-PACIFIC SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ACUTE CONDITIONS, 2018-2030 (USD MILLION)
TABLE 184. ASIA-PACIFIC SPECIALTY PHARMACEUTICALS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 185. ASIA-PACIFIC SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 186. ASIA-PACIFIC SPECIALTY PHARMACEUTICALS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 187. ASIA-PACIFIC SPECIALTY PHARMACEUTICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 188. ASIA-PACIFIC SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PRICING SEGMENT, 2018-2030 (USD MILLION)
TABLE 189. ASIA-PACIFIC SPECIALTY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 190. AUSTRALIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 191. AUSTRALIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ENDOCRINE DISORDERS, 2018-2030 (USD MILLION)
TABLE 193. AUSTRALIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 194. AUSTRALIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 195. AUSTRALIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 196. AUSTRALIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 197. AUSTRALIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. AUSTRALIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. AUSTRALIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. AUSTRALIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 201. AUSTRALIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ACUTE CONDITIONS, 2018-2030 (USD MILLION)
TABLE 202. AUSTRALIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 203. AUSTRALIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 204. AUSTRALIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 205. AUSTRALIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 206. AUSTRALIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PRICING SEGMENT, 2018-2030 (USD MILLION)
TABLE 207. CHINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 208. CHINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 209. CHINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ENDOCRINE DISORDERS, 2018-2030 (USD MILLION)
TABLE 210. CHINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 211. CHINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 212. CHINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 213. CHINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 214. CHINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. CHINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. CHINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. CHINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 218. CHINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ACUTE CONDITIONS, 2018-2030 (USD MILLION)
TABLE 219. CHINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 220. CHINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 221. CHINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 222. CHINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 223. CHINA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PRICING SEGMENT, 2018-2030 (USD MILLION)
TABLE 224. INDIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 225. INDIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 226. INDIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ENDOCRINE DISORDERS, 2018-2030 (USD MILLION)
TABLE 227. INDIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 228. INDIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 229. INDIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 230. INDIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 231. INDIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 232. INDIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. INDIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. INDIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 235. INDIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ACUTE CONDITIONS, 2018-2030 (USD MILLION)
TABLE 236. INDIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 237. INDIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 238. INDIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 239. INDIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 240. INDIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PRICING SEGMENT, 2018-2030 (USD MILLION)
TABLE 241. INDONESIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 242. INDONESIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 243. INDONESIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ENDOCRINE DISORDERS, 2018-2030 (USD MILLION)
TABLE 244. INDONESIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 245. INDONESIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 246. INDONESIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 247. INDONESIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 248. INDONESIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 249. INDONESIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 250. INDONESIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. INDONESIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 252. INDONESIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ACUTE CONDITIONS, 2018-2030 (USD MILLION)
TABLE 253. INDONESIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 254. INDONESIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 255. INDONESIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 256. INDONESIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 257. INDONESIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PRICING SEGMENT, 2018-2030 (USD MILLION)
TABLE 258. JAPAN SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 259. JAPAN SPECIALTY PHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 260. JAPAN SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ENDOCRINE DISORDERS, 2018-2030 (USD MILLION)
TABLE 261. JAPAN SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 262. JAPAN SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 263. JAPAN SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 264. JAPAN SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 265. JAPAN SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 266. JAPAN SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 267. JAPAN SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 268. JAPAN SPECIALTY PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 269. JAPAN SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ACUTE CONDITIONS, 2018-2030 (USD MILLION)
TABLE 270. JAPAN SPECIALTY PHARMACEUTICALS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 271. JAPAN SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 272. JAPAN SPECIALTY PHARMACEUTICALS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 273. JAPAN SPECIALTY PHARMACEUTICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 274. JAPAN SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PRICING SEGMENT, 2018-2030 (USD MILLION)
TABLE 275. MALAYSIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 276. MALAYSIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 277. MALAYSIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ENDOCRINE DISORDERS, 2018-2030 (USD MILLION)
TABLE 278. MALAYSIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 279. MALAYSIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 280. MALAYSIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 281. MALAYSIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 282. MALAYSIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 283. MALAYSIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 284. MALAYSIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 285. MALAYSIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 286. MALAYSIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ACUTE CONDITIONS, 2018-2030 (USD MILLION)
TABLE 287. MALAYSIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 288. MALAYSIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 289. MALAYSIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 290. MALAYSIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 291. MALAYSIA SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PRICING SEGMENT, 2018-2030 (USD MILLION)
TABLE 292. PHILIPPINES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 293. PHILIPPINES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 294. PHILIPPINES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ENDOCRINE DISORDERS, 2018-2030 (USD MILLION)
TABLE 295. PHILIPPINES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 296. PHILIPPINES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 297. PHILIPPINES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 298. PHILIPPINES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 299. PHILIPPINES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 300. PHILIPPINES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 301. PHILIPPINES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 302. PHILIPPINES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 303. PHILIPPINES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ACUTE CONDITIONS, 2018-2030 (USD MILLION)
TABLE 304. PHILIPPINES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 305. PHILIPPINES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 306. PHILIPPINES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 307. PHILIPPINES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 308. PHILIPPINES SPECIALTY PHARMACEUTICALS MARKET SIZE, BY PRICING SEGMENT, 2018-2030 (USD MILLION)
TABLE 309. SINGAPORE SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 310. SINGAPORE SPECIALTY PHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 311. SINGAPORE SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ENDOCRINE DISORDERS, 2018-2030 (USD MILLION)
TABLE 312. SINGAPORE SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
TABLE 313. SINGAPORE SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 314. SINGAPORE SPECIALTY PHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 315. SINGAPORE SPECIALTY PHARMACEUTICALS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 316. SINGAPORE SPECIALTY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 317. SINGAPORE SPECIALTY PHA

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Bristol Myers Squibb Company
  • Endo International PLC
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Hyphens Pharma International Limited
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • UnitedHealth Group
  • Viatris Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Specialty Pharmaceuticals - Global Strategic Business Report - Product Image

Specialty Pharmaceuticals - Global Strategic Business Report

  • Report
  • 291 Pages
  • Global
From
Specialty Pharmaceuticals Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Specialty Pharmaceuticals Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Specialty Pharmaceuticals Market 2024-2028 - Product Image

Specialty Pharmaceuticals Market 2024-2028

  • Report
  • 168 Pages
  • Global
From
Global Specialty Pharmaceutical Partnering Terms and Agreements 2019-2024 - Product Image

Global Specialty Pharmaceutical Partnering Terms and Agreements 2019-2024

  • Report
  • 750 Pages
  • Global
From
Specialty Drug Distribution Market - Global Forecast to 2030 - Product Image

Specialty Drug Distribution Market - Global Forecast to 2030

  • Report
  • 192 Pages
  • Global
From

About the Specialty Pharmaceutical Market

The Specialty Pharmaceutical market is a subset of the Pharmaceutical industry that focuses on the development, production, and distribution of drugs that require special handling, storage, and administration. These drugs are typically used to treat complex, chronic, and rare diseases, and are often more expensive than traditional pharmaceuticals. Specialty Pharmaceuticals are typically biologics, which are drugs derived from living organisms, or small molecule drugs, which are chemically synthesized. Specialty Pharmaceuticals are typically distributed through specialty pharmacies, which are pharmacies that have specialized training and expertise in the handling and administration of these drugs. Specialty pharmacies also provide additional services such as patient education, drug therapy management, and reimbursement support. Some companies in the Specialty Pharmaceutical market include AbbVie, Amgen, Biogen, Gilead Sciences, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.